Savara (SVRA) Other Non Operating Income (2010 - 2026)
Savara (SVRA) reported Other Non Operating Income of $1.7 million for Q1 2026, down 5.01% year-over-year from $1.8 million in Q1 2025, and down 61.12% on a QoQ basis from $4.4 million in Q4 2025.
Savara (SVRA) has 17 years of Other Non Operating Income data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Other Non Operating Income fell 5.01% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (up 147.59% YoY) and the FY2025 annual result came in at $4.7 million, up 9135.29% from the prior year.
- Other Non Operating Income fell to $1.7 million in Q1 2026 per SVRA's latest filing, from $4.4 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $4.4 million in Q4 2025 and bottomed at -$254000.0 in Q1 2022.
- The 5-year median for Other Non Operating Income is $146000.0 (2025), against an average of $715588.2.
- The widest annual swing landed in 2022, when Other Non Operating Income sank 345.61%; it then soared 18162.5% in 2023.
- Tracing SVRA's Other Non Operating Income over 5 years: stood at $668000.0 in 2022, then slumped by 98.2% to $12000.0 in 2023, then jumped by 1708.33% to $217000.0 in 2024, then jumped by 1922.12% to $4.4 million in 2025, then tumbled by 61.12% to $1.7 million in 2026.
- Per Business Quant, the three latest SVRA Other Non Operating Income figures stand at $1.7 million (Q1 2026), $4.4 million (Q4 2025), and $146000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | 4.39 Mn |
| Sep 30, 2025 | 146,000.00 |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 217,000.00 |
| Sep 30, 2024 | -20,000.00 |
| Jun 30, 2024 | 947,000.00 |
| Mar 31, 2024 | -21,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Sep 30, 2023 | 1.45 Mn |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Dec 31, 2022 | 668,000.00 |
| Sep 30, 2022 | -8,000.00 |
| Jun 30, 2022 | 42,000.00 |
| Mar 31, 2022 | -254,000.00 |
| Dec 31, 2021 | -77,000.00 |
| Sep 30, 2021 | -574,000.00 |
| Jun 30, 2021 | -489,000.00 |
| Mar 31, 2021 | -57,000.00 |
| Dec 31, 2020 | -196,000.00 |
| Sep 30, 2020 | 148,000.00 |
| Jun 30, 2020 | 50,000.00 |
| Mar 31, 2020 | 156,000.00 |
| Dec 31, 2019 | -210,000.00 |
| Sep 30, 2019 | 116,000.00 |
| Jun 30, 2019 | 215,000.00 |
| Mar 31, 2019 | 808,000.00 |
| Dec 31, 2018 | -1.17 Mn |
| Sep 30, 2018 | -7,000.00 |
| Jun 30, 2018 | 155,000.00 |
| Mar 31, 2018 | 703,000.00 |
| Dec 31, 2017 | 1.54 Mn |
| Sep 30, 2017 | -391,000.00 |
| Jun 30, 2017 | -1.82 Mn |
| Mar 31, 2017 | -437,000.00 |
| Dec 31, 2016 | -282,000.00 |
| Sep 30, 2016 | 92,000.00 |
| Jun 30, 2016 | -68,000.00 |
| Mar 31, 2016 | 15,000.00 |
| Dec 31, 2015 | -3.06 Mn |
| Sep 30, 2015 | -15,000.00 |
| Jun 30, 2015 | -1,000.00 |
| Mar 31, 2015 | 4,000.00 |
| Dec 31, 2014 | 22,000.00 |
| Jun 30, 2014 | 33,000.00 |
| Mar 31, 2014 | 453,000.00 |
| Dec 31, 2013 | 335.00 |
| Sep 30, 2013 | -137.00 |
| Jun 30, 2013 | 1,172.00 |
| Mar 31, 2013 | -2,370.00 |
| Dec 31, 2012 | 2,433.00 |
| Sep 30, 2012 | 1,099.00 |
| Jun 30, 2012 | -8,890.00 |
| Mar 31, 2012 | 311.00 |
| Dec 31, 2011 | 56,547.00 |
| Sep 30, 2011 | 6,448.00 |
| Jun 30, 2011 | 3,277.00 |
| Mar 31, 2011 | 5,105.00 |
| Dec 31, 2010 | -450.00 |
| Sep 30, 2010 | -2,019.00 |